Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals conducts preclinical animal studies as a standard part of its drug development process. The company’s SEC filings routinely cite the “completion of preclinical laboratory tests, animal studies and formulation studies” as a prerequisite for advancing its oncology drug candidates toward clinical trials. This reliance on animal testing is a standard regulatory requirement for pharmaceutical companies seeking FDA approval for new chemical entities.

The company acknowledges in its public disclosures that animal rights groups and other organizations have attempted to influence or restrict the use of animals in research. Zentalis is listed by Cruelty Free Investing as a company that conducts pre-clinical studies of its drugs on animals. As a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancer, its research pipeline is fundamentally dependent on animal testing to assess the safety and efficacy of its novel compounds.